Full Title: Expanded Access to Convalescent Plasma for the Treatment of Patients with COVID-19

Principal Investigator: Debra Powell, MD

Treatment Objective: This treatment plan will provide access to investigational convalescent plasma for patients in acute care facilities infected with SARS-CoV-2 who have severe or life-threatening COVID-19, or who are judged by a healthcare provider to be at high risk of progression to severe or life-threatening disease. Plasma will be obtained from donors with prior documented SARS-CoV-2 infection.

Inclusion Criteria:
- At least 18 years of age
- Laboratory-confirmed diagnosis of infection with SARS-CoV-2
- Admitted to an acute care facility for the treatment of COVID-19 complications
- Severe or life threatening COVID-19, or judged by the treating provider to be at high risk of progression to severe or life-threatening disease
- Informed consent provided by the patient or healthcare proxy

Affiliations & Sponsors: Mayo Clinic & BARDA

Keywords: SARS-CoV-2, COVID-19, coronavirus, convalescent plasma,